Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ACADIA PHARMACEUTICALS INCACAD · Entity 3913 | EVP, CHIEF LEGAL OFFICER, SEC | March 24, 2026 | March 27, 2026 |
| Adamas Pharmaceuticals IncADMS · Entity 133085 | CBO, GC & Compliance Officer | June 20, 2019 | June 21, 2019 |
| Elicio Therapeutics, Inc.ANGN · Entity 299 | See Remarks | March 02, 2022 | March 04, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ACADIA PHARMACEUTICALS INC
Report date March 24, 2026 · Filed March 27, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 11,280 |
Ending reported balance
After 2026-03-25 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-03-24 · Exercise / conversion · Acquired 7,515 · Balance 15,124 F1: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. Row 2 · 2026-03-25 · Sale · Disposed 3,844 · Balance 11,280 F2: The mandatory sales reported in this Form 4 were made to cover withholding taxes and tax related items imposed by the Issuer in connection with the vesting of restricted stock units, and it is intended to comply with the requirements of Rule 10b5-1(c)(1)(i)(B) under the Exchange Act and be interpreted to meet the requirements of Rule 10b5-1(c). |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 22,547 |
Reported balance
After 2026-03-24 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-03-24 · Exercise / conversion · Disposed 7,515 · Balance 22,547 F1: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F3: The restricted stock units vest in four equal annual installments beginning March 24, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.
F2: The mandatory sales reported in this Form 4 were made to cover withholding taxes and tax related items imposed by the Issuer in connection with the vesting of restricted stock units, and it is intended to comply with the requirements of Rule 10b5-1(c)(1)(i)(B) under the Exchange Act and be interpreted to meet the requirements of Rule 10b5-1(c).
F3: The restricted stock units vest in four equal annual installments beginning March 24, 2026.
Adamas Pharmaceuticals Inc
Report date June 20, 2019 · Filed June 21, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 63,114 |
Reported balance
After 2019-06-20 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2019-06-20 · Sale · Disposed 940 · Balance 63,114 F1: Pursuant to the mandatory sale to cover withholding tax requirements of the issuer's equity incentive plan, the shares were sold to cover the tax obligation realized upon the vesting of restricted stock units. F2: Includes 2,442 shares purchased on 5/31/19 through the issuer's employee stock purchase plan. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the mandatory sale to cover withholding tax requirements of the issuer's equity incentive plan, the shares were sold to cover the tax obligation realized upon the vesting of restricted stock units.
F2: Includes 2,442 shares purchased on 5/31/19 through the issuer's employee stock purchase plan.
Elicio Therapeutics, Inc.
Report date March 02, 2022 · Filed March 04, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.99 · Expires 2032-03-01 | Direct | 175,000 |
Reported balance
After 2022-03-02 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-03-02 · Grant · Acquired 175,000 · Balance 175,000 F1: The total number of options vest in forty-eight (48) successive and equal monthly installments as measured from March 3, 2022 (the "Vesting Commencement Date"), such that 100% of the options will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.99 · Expires 2032-03-01 | Direct | 275,000 |
Reported balance
After 2022-03-02 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2022-03-02 · Grant · Acquired 100,000 · Balance 275,000 F2: The total number of options vest in equal parts on July 31, 2022 and December 31, 2022, such that 100% of the options will be fully vested and exercisable on December 31, 2022. |
Filing footnotes · ownership attribution and instrument terms
F1: The total number of options vest in forty-eight (48) successive and equal monthly installments as measured from March 3, 2022 (the "Vesting Commencement Date"), such that 100% of the options will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date.
F2: The total number of options vest in equal parts on July 31, 2022 and December 31, 2022, such that 100% of the options will be fully vested and exercisable on December 31, 2022.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 25, 2026 Filed Mar 27, 2026 00:00 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | SaleCommon Stock | 3,844 | $21.47 | $82,530.68 |
DisclosureSEC source: 0001568249-26-000005 · form4-03262026_080308.xml · nonDerivative · entry 2 Rhodes Jennifer J · CIK 0001568249 · EVP, CHIEF LEGAL OFFICER, SEC 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,280 F2 · kind: The mandatory sales reported in this Form 4 were made to cover withholding taxes and tax related items imposed by the Issuer in connection with the vesting of restricted stock units, and it is intended to comply with the requirements of Rule 10b5-1(c)(1)(i)(B) under the Exchange Act and be interpreted to meet the requirements of Rule 10b5-1(c). Read SEC document |
| March 24, 2026 Filed Mar 27, 2026 00:00 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionRestricted Stock Units · Derivative | 7,515 | $0.00 | $0.00 |
DisclosureSEC source: 0001568249-26-000005 · form4-03262026_080308.xml · derivative · entry 3 Rhodes Jennifer J · CIK 0001568249 · EVP, CHIEF LEGAL OFFICER, SEC 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,547 Underlying: Common Stock · 7,515 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F3 · derivative.exercise_date: The restricted stock units vest in four equal annual installments beginning March 24, 2026. F3 · derivative.expiration_date: The restricted stock units vest in four equal annual installments beginning March 24, 2026. Read SEC document |
| March 24, 2026 Filed Mar 27, 2026 00:00 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionCommon Stock | 7,515 | $0.00 | $0.00 |
DisclosureSEC source: 0001568249-26-000005 · form4-03262026_080308.xml · nonDerivative · entry 1 Rhodes Jennifer J · CIK 0001568249 · EVP, CHIEF LEGAL OFFICER, SEC 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,124 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| March 06, 2026 Filed Mar 10, 2026 22:00 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | GrantRestricted Stock Units · Derivative | 26,382 | $0.00 | $0.00 |
DisclosureSEC source: 0001568249-26-000004 · form4-03102026_060312.xml · derivative · entry 2 Rhodes Jennifer J · CIK 0001568249 · EVP, CHIEF LEGAL OFFICER, SEC 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,382 Underlying: Common Stock · 26,382 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock. F3 · derivative.exercise_date: The restricted stock units vest in four equal annual installments beginning March 6, 2027. F3 · derivative.expiration_date: The restricted stock units vest in four equal annual installments beginning March 6, 2027. Read SEC document |
| March 06, 2026 Filed Mar 10, 2026 22:00 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | GrantStock Option (Right to Buy) · Derivative | 90,691 | $0.00 Strike: $22.16 | $0.00 |
DisclosureSEC source: 0001568249-26-000004 · form4-03102026_060312.xml · derivative · entry 1 Rhodes Jennifer J · CIK 0001568249 · EVP, CHIEF LEGAL OFFICER, SEC 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 90,691 Underlying: Common Stock · 90,691 shares Expires 2036-03-05 F1 · derivative.exercise_date: 25% of the shares subject to the Stock Option will vest and become exercisable on March 6, 2027. The remaining shares vest and become exercisable in 36 equal monthly installments thereafter. Read SEC document |
| February 09, 2026 Filed Feb 10, 2026 23:00 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | SaleCommon Stock | 6,950 | $23.38 | $162,491.00 |
DisclosureSEC source: 0001568249-26-000002 · form4-02102026_060201.xml · nonDerivative · entry 2 Rhodes Jennifer J · CIK 0001568249 · EVP, CHIEF LEGAL OFFICER, SEC 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,609 F3 · kind: The mandatory sales reported in this Form 4 were made to cover withholding taxes and tax related items imposed by the Issuer in connection with the vesting of restricted stock units, and it is intended to comply with the requirements of Rule 10b5-1(c)(1)(i)(B) under the Exchange Act and be interpreted to meet the requirements of Rule 10b5-1(c). F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.38 to $23.40, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| February 06, 2026 Filed Feb 10, 2026 23:00 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionRestricted Stock Units · Derivative | 12,944 | $0.00 | $0.00 |
DisclosureSEC source: 0001568249-26-000002 · form4-02102026_060201.xml · derivative · entry 3 Rhodes Jennifer J · CIK 0001568249 · EVP, CHIEF LEGAL OFFICER, SEC 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,945 Underlying: Common Stock · 12,944 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F5 · derivative.exercise_date: 50% of the restricted stock units vested on February 6, 2026 and 25% vest on each of February 6, 2027 and February 6, 2028. F5 · derivative.expiration_date: 50% of the restricted stock units vested on February 6, 2026 and 25% vest on each of February 6, 2027 and February 6, 2028. Read SEC document |
| February 06, 2026 Filed Feb 10, 2026 23:00 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionCommon Stock | 12,944 | $0.00 | $0.00 |
DisclosureSEC source: 0001568249-26-000002 · form4-02102026_060201.xml · nonDerivative · entry 1 Rhodes Jennifer J · CIK 0001568249 · EVP, CHIEF LEGAL OFFICER, SEC 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,559 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F2 · balance_after: Includes 595 shares of the Issuer's common stock acquired by the reporting person on May 15, 2025 pursuant to an employee stock purchase plan. Read SEC document |
| March 24, 2025 Filed Mar 27, 2025 00:03 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | GrantRestricted Stock Units · Derivative | 30,062 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-009073 · form4-03272025_120324.xml · derivative · entry 3 Rhodes Jennifer J · CIK 0001568249 · EVP, CHIEF LEGAL OFFICER, SEC 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,062 Underlying: Common Stock · 30,062 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock. F4 · derivative.exercise_date: The restricted stock units vest in four equal annual installments beginning March 24, 2026. F4 · derivative.expiration_date: The restricted stock units vest in four equal annual installments beginning March 24, 2026. Read SEC document |
| March 24, 2025 Filed Mar 27, 2025 00:03 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | GrantStock Option (Right to Buy) · Derivative | 102,289 | $0.00 Strike: $17.23 | $0.00 |
DisclosureSEC source: 0001415889-25-009073 · form4-03272025_120324.xml · derivative · entry 2 Rhodes Jennifer J · CIK 0001568249 · EVP, CHIEF LEGAL OFFICER, SEC 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 102,289 Underlying: Common Stock · 102,289 shares Expires 2035-03-23 F2 · derivative.exercise_date: 25% of the shares subject to the Stock Option will vest and become exercisable on March 24, 2026. The remaining shares vest and become exercisable in 36 equal monthly installments thereafter. Read SEC document |
| February 06, 2024 Filed Feb 8, 2024 22:09 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | GrantRestricted Stock Units · Derivative | 25,889 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-003039 · form4-02082024_100202.xml · derivative · entry 2 Rhodes Jennifer J · CIK 0001568249 · EVP, CHIEF LEGAL OFFICER, SEC 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,889 Underlying: Common Stock · 25,889 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F3 · derivative.exercise_date: 50% of the restricted stock units vest on February 6, 2026 and 25% vest on each of February 6, 2027 and February 6, 2028. F3 · derivative.expiration_date: 50% of the restricted stock units vest on February 6, 2026 and 25% vest on each of February 6, 2027 and February 6, 2028. Read SEC document |
| February 06, 2024 Filed Feb 8, 2024 22:09 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | GrantStock Option (Right to Buy) · Derivative | 126,589 | $0.00 Strike: $25.74 | $0.00 |
DisclosureSEC source: 0001415889-24-003039 · form4-02082024_100202.xml · derivative · entry 1 Rhodes Jennifer J · CIK 0001568249 · EVP, CHIEF LEGAL OFFICER, SEC 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 126,589 Underlying: Common Stock · 126,589 shares Expires 2034-02-05 F1 · derivative.exercise_date: 25% of the shares subject to the Stock Option will vest and become exercisable on February 6, 2025. The remaining shares vest and become exercisable in 36 equal monthly installments thereafter. Read SEC document |
| March 02, 2022 Filed Mar 4, 2022 16:21 UTC | Elicio Therapeutics, Inc. ANGN · Entity 299 | GrantStock Option (Right to Buy) · Derivative | 100,000 | $0.00 Strike: $1.99 | $0.00 |
DisclosureSEC source: 0001601485-22-000012 · wf-form4_164642885246988.xml · derivative · entry 2 Rhodes Jennifer J · CIK 0001568249 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 275,000 Underlying: Common Stock · 100,000 shares Expires 2032-03-01 F2 · derivative.exercise_date: The total number of options vest in equal parts on July 31, 2022 and December 31, 2022, such that 100% of the options will be fully vested and exercisable on December 31, 2022. Read SEC document |
| March 02, 2022 Filed Mar 4, 2022 16:21 UTC | Elicio Therapeutics, Inc. ANGN · Entity 299 | GrantStock Option (Right to Buy) · Derivative | 175,000 | $0.00 Strike: $1.99 | $0.00 |
DisclosureSEC source: 0001601485-22-000012 · wf-form4_164642885246988.xml · derivative · entry 1 Rhodes Jennifer J · CIK 0001568249 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 175,000 Underlying: Common Stock · 175,000 shares Expires 2032-03-01 F1 · derivative.exercise_date: The total number of options vest in forty-eight (48) successive and equal monthly installments as measured from March 3, 2022 (the "Vesting Commencement Date"), such that 100% of the options will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date. Read SEC document |
| December 14, 2021 Filed Dec 15, 2021 16:06 UTC | Elicio Therapeutics, Inc. ANGN · Entity 299 | SaleCommon Stock | 451 | $2.42 | $1,090.11 |
DisclosureSEC source: 0001601485-21-000083 · wf-form4_163960237655604.xml · nonDerivative · entry 1 Rhodes Jennifer J · CIK 0001568249 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,399 F1 · kind: The shares reported in this Form 4 were sold pursuant to a 10b5-1 trading plan adopted by the reporting person solely to satisfy tax or other government withholding obligations in connection with the vesting of Restricted Stock Units ("RSUs") granted by the Issuer. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.41 to $2.42 inclusive. Read SEC document |
| November 15, 2021 Filed Nov 16, 2021 16:09 UTC | Elicio Therapeutics, Inc. ANGN · Entity 299 | SaleCommon Stock | 433 | $4.40 | $1,905.20 |
DisclosureSEC source: 0001601485-21-000072 · wf-form4_163709656126099.xml · nonDerivative · entry 1 Rhodes Jennifer J · CIK 0001568249 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,850 F1 · kind: The shares reported in this Form 4 were sold pursuant to a 10b5-1 trading plan adopted by the reporting person solely to satisfy tax or other government withholding obligations in connection with the vesting of Restricted Stock Units ("RSUs") granted by the Issuer. Read SEC document |
| October 14, 2021 Filed Oct 15, 2021 16:10 UTC | Elicio Therapeutics, Inc. ANGN · Entity 299 | SaleCommon Stock | 430 | $8.65 | $3,719.50 |
DisclosureSEC source: 0001601485-21-000060 · wf-form4_163432858580303.xml · nonDerivative · entry 1 Rhodes Jennifer J · CIK 0001568249 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,283 F1 · kind: The shares reported in this Form 4 were sold pursuant to a 10b5-1 trading plan adopted by the reporting person solely to satisfy tax or other government withholding obligations in connection with the vesting of Restricted Stock Units ("RSUs") granted by the Issuer. Read SEC document |
| September 14, 2021 Filed Sep 15, 2021 16:31 UTC | Elicio Therapeutics, Inc. ANGN · Entity 299 | SaleCommon Stock | 430 | $10.64 | $4,575.20 |
DisclosureSEC source: 0001601485-21-000056 · wf-form4_163173783565355.xml · nonDerivative · entry 1 Rhodes Jennifer J · CIK 0001568249 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,713 F1 · kind: The shares reported in this Form 4 were sold pursuant to a 10b5-1 trading plan adopted by the reporting person solely to satisfy tax or other government withholding obligations in connection with the vesting of Restricted Stock Units ("RSUs") granted by the Issuer. Read SEC document |
| August 16, 2021 Filed Aug 17, 2021 16:05 UTC | Elicio Therapeutics, Inc. ANGN · Entity 299 | SaleCommon Stock | 445 | $10.68 | $4,752.60 |
DisclosureSEC source: 0001601485-21-000050 · wf-form4_162923072024903.xml · nonDerivative · entry 1 Rhodes Jennifer J · CIK 0001568249 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,143 F1 · kind: The shares reported in this Form 4 were sold pursuant to a 10b5-1 trading plan adopted by the reporting person solely to satisfy tax or other government withholding obligations in connection with the vesting of Restricted Stock Units ("RSUs") granted by the Issuer. Read SEC document |
| July 21, 2021 Filed Jul 22, 2021 18:06 UTC | Elicio Therapeutics, Inc. ANGN · Entity 299 | SaleCommon Stock | 432 | $10.94 | $4,726.08 |
DisclosureSEC source: 0001601485-21-000040 · wf-form4_162699156354918.xml · nonDerivative · entry 1 Rhodes Jennifer J · CIK 0001568249 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,588 F1 · kind: The shares reported in this Form 4 were sold pursuant to a 10b5-1 trading plan adopted by the reporting person solely to satisfy tax or other government withholding obligations in connection with the vesting of Restricted Stock Units ("RSUs") granted by the Issuer. Read SEC document |
| July 14, 2021 Filed Jul 15, 2021 16:08 UTC | Elicio Therapeutics, Inc. ANGN · Entity 299 | SaleCommon Stock | 431 | $11.01 | $4,745.31 |
DisclosureSEC source: 0001601485-21-000033 · wf-form4_162637966140096.xml · nonDerivative · entry 1 Rhodes Jennifer J · CIK 0001568249 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,589 F1 · kind: The shares reported in this Form 4 were sold pursuant to a 10b5-1 trading plan adopted by the reporting person solely to satisfy tax or other government withholding obligations in connection with the vesting of Restricted Stock Units ("RSUs") granted by the Issuer. Read SEC document |
| June 14, 2021 Filed Jun 16, 2021 16:06 UTC | Elicio Therapeutics, Inc. ANGN · Entity 299 | SaleCommon Stock | 427 | $13.27 | $5,666.29 |
DisclosureSEC source: 0001601485-21-000027 · wf-form4_162387395891013.xml · nonDerivative · entry 1 Rhodes Jennifer J · CIK 0001568249 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,020 F1 · kind: The shares reported in this Form 4 were sold pursuant to a 10b5-1 trading plan adopted by the reporting person solely to satisfy tax or other government withholding obligations in connection with the vesting of Restricted Stock Units ("RSUs") granted by the Issuer. Read SEC document |
| May 14, 2021 Filed May 18, 2021 16:04 UTC | Elicio Therapeutics, Inc. ANGN · Entity 299 | SaleCommon Stock | 440 | $13.92 | $6,124.80 |
DisclosureSEC source: 0001601485-21-000023 · wf-form4_162136823397793.xml · nonDerivative · entry 1 Rhodes Jennifer J · CIK 0001568249 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,447 F1 · kind: The shares reported in this Form 4 were sold pursuant to a 10b5-1 trading plan adopted by the reporting person solely to satisfy tax or other government withholding obligations in connection with the vesting of Restricted Stock Units ("RSUs") granted by the Issuer. Read SEC document |
| April 15, 2021 Filed Apr 15, 2021 16:05 UTC | Elicio Therapeutics, Inc. ANGN · Entity 299 | SaleCommon Stock | 399 | $15.01 | $5,988.99 |
DisclosureSEC source: 0001601485-21-000011 · wf-form4_161851712866164.xml · nonDerivative · entry 1 Rhodes Jennifer J · CIK 0001568249 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,887 F1 · kind: The shares reported in this Form 4 were effected pursuant to a 10b-5-1 trading plan adopted by the reporting person solely to satisfy tax or other government withholding obligations in connection with the vesting of shares subject to a Restricted Stock Units ("RSUs") of the Issuer. Read SEC document |
| March 13, 2021 Filed Mar 16, 2021 16:11 UTC | Elicio Therapeutics, Inc. ANGN · Entity 299 | SaleCommon Stock | 499 | $20.45 | $10,204.55 |
DisclosureSEC source: 0001567619-21-006400 · doc1.xml · nonDerivative · entry 1 Rhodes Jennifer J · CIK 0001568249 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,286 F1 · kind: The shares were sold to the Issuer solely to satisfy tax or other government withholding obligations in connection with the vesting of shares subject to a Restricted Stock Units ("RSUs") of the Issuer. Read SEC document |
| February 13, 2021 Filed Feb 17, 2021 20:10 UTC | Elicio Therapeutics, Inc. ANGN · Entity 299 | SaleCommon Stock | 457 | $19.54 | $8,929.78 |
DisclosureSEC source: 0001567619-21-004331 · doc1.xml · nonDerivative · entry 1 Rhodes Jennifer J · CIK 0001568249 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,785 F1 · kind: The shares were sold solely to satisfy tax or other government withholding obligations in connection with the vesting of shares subject to a Restricted Stock Units ("RSUs") of the Issuer. Read SEC document |
| February 04, 2021 Filed Feb 8, 2021 12:56 UTC | Elicio Therapeutics, Inc. ANGN · Entity 299 | GrantStock Option (Right to Buy) · Derivative | 70,012 | $0.00 Strike: $16.00 | $0.00 |
DisclosureSEC source: 0001567619-21-002410 · doc1.xml · derivative · entry 1 Rhodes Jennifer J · CIK 0001568249 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,012 Underlying: Common Stock · 70,012 shares Expires 2031-02-03 F1 · derivative.exercise_date: 1/48th of the total number of shares vest in forty-eight (48) successive and equal monthly installments measured from February 4, 2021 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date. Read SEC document |
| June 20, 2019 Filed Jun 21, 2019 17:38 UTC | Adamas Pharmaceuticals Inc ADMS · Entity 133085 | SaleCommon Stock | 940 | $5.35 | $5,029.00 |
DisclosureSEC source: 0001209191-19-038602 · doc4.xml · nonDerivative · entry 1 Rhodes Jennifer J · CIK 0001568249 · CBO, GC & Compliance Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,114 F1 · kind: Pursuant to the mandatory sale to cover withholding tax requirements of the issuer's equity incentive plan, the shares were sold to cover the tax obligation realized upon the vesting of restricted stock units. F2 · balance_after: Includes 2,442 shares purchased on 5/31/19 through the issuer's employee stock purchase plan. Read SEC document |
| April 08, 2019 Filed Apr 10, 2019 16:33 UTC | Adamas Pharmaceuticals Inc ADMS · Entity 133085 | GrantStock Option (Right to Buy) · Derivative | 60,000 | $0.00 Strike: $6.81 | $0.00 |
DisclosureSEC source: 0001209191-19-024244 · doc4.xml · derivative · entry 2 Rhodes Jennifer J · CIK 0001568249 · CBO, GC & Compliance Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires 2029-04-07 F2 · derivative.exercise_date: The Option shares shall vest as follows: 1/48th of the option shares shall vest on the 1st of each month beginning with May 1, 2019, subject to Reporting Person's Continuous Service as of each such date. Read SEC document |
| April 08, 2019 Filed Apr 10, 2019 16:33 UTC | Adamas Pharmaceuticals Inc ADMS · Entity 133085 | GrantCommon Stock | 30,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-024244 · doc4.xml · nonDerivative · entry 1 Rhodes Jennifer J · CIK 0001568249 · CBO, GC & Compliance Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,612 F1 · shares: The shares of Common Stock are to be acquired upon the vesting of certain Restricted Stock Units granted to the Reporting Person. The Restricted Stock Units shall vest as follows: 25% of the total number of Restricted Stock Units will vest on each of March 20, 2020, March 20, 2021, March 20, 2022 and March 20, 2023, subject to Reporting Person's Continuous Service as of each such date. Read SEC document |
| March 20, 2019 Filed Mar 21, 2019 16:39 UTC | Adamas Pharmaceuticals Inc ADMS · Entity 133085 | SaleCommon Stock | 1,792 | $7.99 | $14,318.08 |
DisclosureSEC source: 0001209191-19-020769 · doc4.xml · nonDerivative · entry 1 Rhodes Jennifer J · CIK 0001568249 · CBO, GC & Compliance Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,612 F1 · kind: Pursuant to the mandatory sale to cover withholding tax requirements of the issuer's equity incentive plan, the shares were sold to cover the tax obligation realized upon the vesting of restricted stock units. F2 · price: The shares were sold at prices ranging from $7.94 to $8.03. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| December 20, 2018 Filed Dec 21, 2018 16:47 UTC | Adamas Pharmaceuticals Inc ADMS · Entity 133085 | SaleCommon Stock | 425 | $7.52 | $3,196.00 |
DisclosureSEC source: 0001209191-18-063937 · doc4.xml · nonDerivative · entry 1 Rhodes Jennifer J · CIK 0001568249 · CBO, GC & Compliance Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,404 F1 · kind: Pursuant to the mandatory sale to cover withholding tax requirements of the issuer's equity incentive plan, the shares were sold to cover the tax obligation realized upon the vesting of restricted stock units. F2 · price: The shares were sold at prices ranging from $7.50 to $7.52. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. F3 · balance_after: Includes 35 shares purchased on 11/30/18 through the issuer's employee stock purchase plan. Read SEC document |
| June 21, 2018 Filed Jun 22, 2018 16:50 UTC | Adamas Pharmaceuticals Inc ADMS · Entity 133085 | SaleCommon Stock | 1,002 | $25.48 | $25,530.96 |
DisclosureSEC source: 0001209191-18-039257 · doc4.xml · nonDerivative · entry 1 Rhodes Jennifer J · CIK 0001568249 · CBO, GC & Compliance Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,794 F1 · kind: Pursuant to the mandatory sale to cover withholding tax requirements of the issuer's equity incentive plan, the shares were sold to cover the tax obligation realized upon the vesting of restricted stock units. F2 · price: The shares were sold at prices ranging from $25.45 to $25.50. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. F3 · balance_after: Includes 668 shares purchased on 5/31/18 through the issuer's employee stock purchase plan. Read SEC document |
| March 21, 2018 Filed Mar 22, 2018 17:56 UTC | Adamas Pharmaceuticals Inc ADMS · Entity 133085 | SaleCommon Stock | 982 | $25.89 | $25,423.98 |
DisclosureSEC source: 0001209191-18-021317 · doc4.xml · nonDerivative · entry 1 Rhodes Jennifer J · CIK 0001568249 · CBO, GC & Compliance Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,128 F1 · kind: Pursuant to the mandatory sale to cover withholding tax requirements of the issuer's equity incentive plan, the shares were sold to cover the tax obligation realized upon the vesting of restricted stock units. F2 · price: The shares were sold at prices ranging from $25.81 to $25.95. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| March 06, 2018 Filed Mar 9, 2018 20:53 UTC | Adamas Pharmaceuticals Inc ADMS · Entity 133085 | GrantStock Option (Right to Buy) · Derivative | 37,500 | $0.00 Strike: $25.66 | $0.00 |
DisclosureSEC source: 0001209191-18-018676 · doc4.xml · derivative · entry 2 Rhodes Jennifer J · CIK 0001568249 · CBO, GC & Compliance Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,500 Underlying: Common Stock · 37,500 shares Expires 2028-03-05 F2 · derivative.exercise_date: The Option shares shall vest as follows: 1/48th of the option shares shall vest on the 1st of each month beginning with April 1, 2018, subject to Reporting Person's Continuous Service as of each such date. Read SEC document |
| March 06, 2018 Filed Mar 9, 2018 20:53 UTC | Adamas Pharmaceuticals Inc ADMS · Entity 133085 | GrantCommon Stock | 6,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-018676 · doc4.xml · nonDerivative · entry 1 Rhodes Jennifer J · CIK 0001568249 · CBO, GC & Compliance Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,110 F1 · shares: The shares of Common Stock are to be acquired upon the vesting of certain Restricted Stock Units granted to the Reporting Person. The Restricted Stock Units shall vest as follows: 25% of the total number of Restricted Stock Units will vest on each of March 20, 2019, March 20, 2020, March 20, 2021 and March 20, 2022, subject to Reporting Person's Continuous Service as of each such date. Read SEC document |
| December 21, 2017 Filed Dec 21, 2017 16:43 UTC | Adamas Pharmaceuticals Inc ADMS · Entity 133085 | SaleCommon Stock | 440 | $32.30 | $14,212.00 |
DisclosureSEC source: 0001209191-17-066810 · doc4.xml · nonDerivative · entry 1 Rhodes Jennifer J · CIK 0001568249 · CBO, GC & Compliance Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,860 F1 · kind: Pursuant to the mandatory sale to cover withholding tax requirements of the issuer's equity incentive plan, the shares were sold to cover the tax obligation realized upon the vesting of restricted stock units. F2 · balance_after: Includes 845 shares purchased on 11/30/17 through the issuer's employee stock purchase plan. Read SEC document |
| June 21, 2017 Filed Jun 22, 2017 17:05 UTC | Adamas Pharmaceuticals Inc ADMS · Entity 133085 | SaleCommon Stock | 1,041 | $17.53 | $18,253.73 |
DisclosureSEC source: 0001209191-17-041439 · doc4.xml · nonDerivative · entry 1 Rhodes Jennifer J · CIK 0001568249 · CBO, GC & Compliance Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,455 F1 · kind: Pursuant to the mandatory sale to cover withholding tax requirements of the issuer's equity incentive plan, the shares were sold to cover the tax obligation realized upon the vesting of restricted stock units. F2 · price: The shares were sold at prices ranging from $17.531 to $17.535. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. F3 · balance_after: Includes 1,259 shares purchased on 5/31/17 through the issuer's employee stock purchase plan. Read SEC document |
| January 18, 2017 Filed Jan 20, 2017 18:15 UTC | Adamas Pharmaceuticals Inc ADMS · Entity 133085 | GrantStock Option (Right to Buy) · Derivative | 67,500 | $0.00 Strike: $16.61 | $0.00 |
DisclosureSEC source: 0001209191-17-004978 · doc4.xml · derivative · entry 2 Rhodes Jennifer J · CIK 0001568249 · CBO, GC & Compliance Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,500 Underlying: Common Stock · 67,500 shares Expires 2027-01-17 F2 · derivative.exercise_date: The shares subject to the option shall become vested according to the following schedule: 1/48th of the shares subject to the option shall vest monthly beginning on February 1, 2017 for 48 months. Read SEC document |
| January 18, 2017 Filed Jan 20, 2017 18:15 UTC | Adamas Pharmaceuticals Inc ADMS · Entity 133085 | GrantCommon Stock | 11,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-004978 · doc4.xml · nonDerivative · entry 1 Rhodes Jennifer J · CIK 0001568249 · CBO, GC & Compliance Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,187 F1 · shares: Represents the grant of restricted stock units that vest 1/4th on each of March 20, 2018, March 20, 2019, March 20, 2020 and March 20, 2021. Read SEC document |
| November 07, 2016 Filed Nov 8, 2016 16:33 UTC | Adamas Pharmaceuticals Inc ADMS · Entity 133085 | GrantStock Option (Right to Buy) · Derivative | 28,125 | $0.00 Strike: $14.26 | $0.00 |
DisclosureSEC source: 0001209191-16-148867 · doc4.xml · derivative · entry 2 Rhodes Jennifer J · CIK 0001568249 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,125 Underlying: Common Stock · 28,125 shares Expires 2026-11-06 F2 · derivative.exercise_date: The shares subject to the option shall become vested according to the following schedule: 25% of the shares subject to the option shall vest on October 29, 2017, and the remaining shares will vest in equal monthly installments over the next 36 months. Read SEC document |
| November 07, 2016 Filed Nov 8, 2016 16:33 UTC | Adamas Pharmaceuticals Inc ADMS · Entity 133085 | GrantCommon Stock | 4,687 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-16-148867 · doc4.xml · nonDerivative · entry 1 Rhodes Jennifer J · CIK 0001568249 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,937 F1 · shares: Represents the grant of restricted stock units that vest 1/4th on each of December 20, 2017, December 20, 2018, December 20, 2019, and December 20, 2020. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.